**Monday, 12 November 2018**

8:45 – 13:45 Poster session I
12:45 – 13:45 Poster author discussion hour

Which model(s) are used to assess individual-level surrogacy in oncology using Kendall’s tau? A systematic literature review

PMU24 - E6

Physicians preferences with respect to adherence programs: A Discrete Choice Experiment

PMU81 - F26

15:45 – 19:15 Research poster session II
18:15 – 19:15 Poster author discussion hour

Treatment and characteristics of pediatric patients with focal epilepsy in Germany

PND15 - L18

Incidence of Epilepsy after strokes and real-world antiepileptic drug treatment

PND19 - L22

Incidence and treatment of patients with status epilepticus: An analysis of German claims data

PND20 - L23

17:00 – 18:00 Breakout session 3

Comparing mixture cure models with standard parametric models within three- and five-state partition survival frameworks

P6: Modeling - Room: 212 (F2)

**Tuesday, 13 November 2018**

8:45 – 13:30 Poster session III
12:30 – 13:30 Poster author discussion hour

Baseline characteristics of German diabetes mellitus type-2 patients who initiated insulin usage: A claims data analysis

PDB24 - A23

The cost-effectiveness of metformin in pre-diabetics: A systematic literature review of health economic evaluations

PDB65 - B28

Adverse events associated with the treatment of inflammatory bowel disease in Germany

PGI1 - D31

Non-persistence with immunosuppressant, anti-tumor necrosis factor, and anti-integrin agents in patients with inflammatory bowel disease: A retrospective claims data analysis in Germany

PGI42 - F1

11:00 – 12:00 Breakout session 5

Novel approaches to common challenges in modelling of survival outcomes for cost-effectiveness analyses in oncology

WB - Room: 115+116 (P1)

Mixture methods incorporating general population mortality in the likelihood function of parametric distributions

PB: Research on methods - Room: 112 (P1)

15:30 – 19:00 Research poster session IV
18:00 – 19:00 Poster author discussion hour

Adherence to oral anticoagulation treatment in atrial fibrillation and the impact of patient satisfaction

PCV142 - D32

Treatment burden associated with different anticoagulation strategies of atrial fibrillation patients: an observational study in Germany, Sweden and Switzerland based on the Anti-Clot Treatment Scale

PCV152 - E7

Association between health-related quality of life and atrial fibrillation symptom burden: results of a study on atrial fibrillation patients in Germany, Sweden and Switzerland

PCV157 - E12

Identification of dose-escalation in biologics therapy based on claims data: the example in inflammatory bowel disease

PRM2 - E18

Pre-approval simulation of real-world outcomes: development of a methodological framework

PRM15 - E30

The use of external data to better inform survival extrapolations in submissions to the National Institute for Health and Care Excellence (NICE)

PRM80 - G21

Advanced NMA techniques in NICE HTA submissions

PRM106 - H12

Application and acceptance of complex survival extrapolation methods in HTA submissions

PRM111 - H16

Bootstrapping progression-free survival and overall survival to capture their correlation in probabilistic sensitivity analyses

PRM122 - H27

The DIVE framework for using different types of information in estimating lifetime clinically plausible effectiveness

PRM138 - I8

Comparison of novel Bayesian methods using external data to improve survival estimations from immature survival

PRM141 - I11

Validation of the English version of the Adherence Assessment Questionnaire (AAQ)

PRM208 - K6

The use of the two-stage method in adjusting for treatment crossover: A simulation study

PRM233 - K31

Hazard ratio estimation using different methods: an impact assessment

PRM234 - K32

Calibrating matching adjusted indirect comparison estimate to real-world population

PRM236 - K34

An out-of-sample method to quantify systematic error in unanchored indirect comparisons

PRM241 - L4

Network meta-analyses on survival data: a comparison and guidance for different methodologies

PRM243 - L6

Quantifying systematic error in unanchored indirect comparisons: the in-sample method

PRM255 - L17

Does the design of a discrete choice analysis influence its results? An example study of women's preferences for contraceptive products.

PRM264 - L26

**Wednesday, 14 November 2018**

8:45 – 13:15 Poster session V
12:15 – 13:15 Poster author discussion hour

Real-world treatment of patients with advanced non-small cell lung cancer: Results of a claims data study of patients in Germany

PCN48 - B12

Prevalence and incidence of different cancer types in Germany: An epidemiological analysis based on claims data of more than 2.9 million insured person.

PCN52 - B16

Association between hazard ratios of surrogate time-to-event endpoints and overall survival in advanced/metastatic cancers

PCN59 - B23

Real-world overall survival of patients with advanced non-small cell lung cancer: Results of a claims data study of patients in Germany

PCN60 - B24

Real-world progression-free survival of patients with advanced non-small cell lung cancer: Results of a claims data study of patients in Germany

PCN61 - B25

Review of NICE HTA submissions including matching-adjusted indirect comparisons and simulated treatment comparisons

PCN63 - B27

Review of NICE HTA submissions including methodologies adjusting for overall survival in the presence of treatment switching

PCN64 - B28

Landmark analyses in oncology – seeing beyond the surface and proposing a structured data analysis checklist

PCN66 - B30

Health-technology assessment in oncology: Results of a review of decisions in Germany

PCN314 - E30

Relationship between two cancer clinical benefit frameworks and health technology decisions in three European countries;

PCN316 - E32

Recommendations of Spanish therapeutic positioning reports for new oncology drugs since year 2013

PCN20 - J1

Comparison of recommendations for cancer drugs carried out by three HTA bodies (2015-2018): NICE technology appraisals, German federal joint committee and Spanish therapeutic positioning report

PCN221 - J2

Real-world treatment of patients with osteoporosis in Germany: prevalence and incidence of patients with osteoporosis and increased fracture risk

PMS13 - L17